124 related articles for article (PubMed ID: 19202572)
1. Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.
Kaufman J; Griffiths TA; Surette MG; Ness S; Rioux KP
Inflamm Bowel Dis; 2009 Jul; 15(7):985-96. PubMed ID: 19202572
[TBL] [Abstract][Full Text] [Related]
2. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.
Zhang S; Fu J; Dogan B; Scherl EJ; Simpson KW
J Antibiot (Tokyo); 2018 Nov; 71(11):950-961. PubMed ID: 30050110
[TBL] [Abstract][Full Text] [Related]
3. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis.
Swidsinski A; Loening-Baucke V; Bengmark S; Lochs H; Dörffel Y
Inflamm Bowel Dis; 2007 Jan; 13(1):51-6. PubMed ID: 17206639
[TBL] [Abstract][Full Text] [Related]
4. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
5. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome.
McCoubrey LE; Seegobin N; Sangfuang N; Moens F; Duyvejonck H; Declerck E; Dierick A; Marzorati M; Basit AW
J Control Release; 2024 May; 369():630-641. PubMed ID: 38599548
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
7. [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
Allgayer H; Klotz U; Böhne P; Schmidt M; Kruis W
Z Gastroenterol; 1994 Nov; 32(11):647-50. PubMed ID: 7886975
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Sawarkar SP; Deshpande SG; Bajaj AN; Nikam VS
AAPS PharmSciTech; 2015 Dec; 16(6):1445-54. PubMed ID: 26017284
[TBL] [Abstract][Full Text] [Related]
9. Bacterial immune interaction in experimental colitis.
Xue LY; Ouyang Q; Zhou XG; Huang ZH; Chen W; Chen M; Yu LM
J Dig Dis; 2013 Oct; 14(10):526-35. PubMed ID: 23734583
[TBL] [Abstract][Full Text] [Related]
10. Mucoadhesive Mesalamine Prodrug Nanoassemblies to Target Intestinal Macrophages for the Treatment of Inflammatory Bowel Disease.
Park B; Han G; Jin DY; Gil KC; Shin D; Lee J; Park JY; Jang H; Park D; Lee S; Kim K; Yang Y; Kim Y; Kim JS; Kim SH; Shim MK
ACS Nano; 2024 Jun; 18(25):16297-16311. PubMed ID: 38867457
[TBL] [Abstract][Full Text] [Related]
11. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1.
Khare V; Lyakhovich A; Dammann K; Lang M; Borgmann M; Tichy B; Pospisilova S; Luciani G; Campregher C; Evstatiev R; Pflueger M; Hundsberger H; Gasche C
Biochem Pharmacol; 2013 Jan; 85(2):234-44. PubMed ID: 23146664
[TBL] [Abstract][Full Text] [Related]
12. 5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells.
McKenzie SM; Doe WF; Buffinton GD
Gut; 1999 Feb; 44(2):180-5. PubMed ID: 9895376
[TBL] [Abstract][Full Text] [Related]
13. Acetylsalicylic acid-tris-hydroxymethyl-aminomethane reduces colon mucosal damage without causing gastric side effects in a rat model of colitis.
Varga G; Ugocsai M; Hartmann P; Lajkó N; Molnár R; Szűcs S; Jász DK; Érces D; Ghyczy M; Tóth G; Boros M
Inflammopharmacology; 2018 Feb; 26(1):261-271. PubMed ID: 28451776
[TBL] [Abstract][Full Text] [Related]
14. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
15. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
16. Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine.
Subramanian S; Rhodes JM; Hart CA; Tam B; Roberts CL; Smith SL; Corkill JE; Winstanley C; Virji M; Campbell BJ
Inflamm Bowel Dis; 2008 Feb; 14(2):162-75. PubMed ID: 17941093
[TBL] [Abstract][Full Text] [Related]
17. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
18. Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation.
Khare V; Krnjic A; Frick A; Gmainer C; Asboth M; Jimenez K; Lang M; Baumgartner M; Evstatiev R; Gasche C
Sci Rep; 2019 Feb; 9(1):2842. PubMed ID: 30809073
[TBL] [Abstract][Full Text] [Related]
19. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
Bautzová T; Rabišková M; Lamprecht A
Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
[TBL] [Abstract][Full Text] [Related]
20. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.
Gisbert JP; Luna M; González-Lama Y; Pousa ID; Velasco M; Moreno-Otero R; Maté J
Gastroenterol Hepatol; 2008 Oct; 31(8):477-84. PubMed ID: 18928745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
